1. Immunology/Inflammation
  2. Interleukin Related
  3. Tildrakizumab

Tildrakizumab  (Synonyms: SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody)

Cat. No.: HY-P99256 Purity: 99.46%
Data Sheet SDS COA Technical Support

Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.

For research use only. We do not sell to patients.

CAS No. : 1326244-10-3

Size Price Stock Quantity
1 mg USD 400 In-stock
5 mg USD 1040 In-stock
10 mg USD 1665 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it tomorrow February 19 by noon. Order within 1 hrs 48 mins.

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3].

IC50 & Target

IL-23[1]

In Vitro

Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2].
Tildrakizumab reduces IL-23’s affinity for IL-23Rα through a negative allosteric modulation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tildrakizumab (100 mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT04112810Medical College of Wisconsin
Hematologic Malignancies
March 1, 2020Phase 2
NCT04229836Almirall, S.A.
Plaque Psoriasis
December 17, 2019Phase 4
NCT01722331Sun Pharmaceutical Industries Limited
Plaque Psoriasis
December 6, 2012Phase 3
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tildrakizumab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tildrakizumab
Cat. No.:
HY-P99256
Quantity:
MCE Japan Authorized Agent: